01.12.2012 Views

MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME

MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME

MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

409<br />

APPENDIX I: Dr Tony Johnson, Deputy Director of the MRC Biostatistical Unit, Cambridge<br />

The UK <strong>ME</strong>/CFS community noted with some surprise the <strong>in</strong>volvement of Dr Tony Johnson <strong>in</strong> the PACE<br />

Trial because his published views on psychiatric trials are already known. In 1998 he published a major<br />

review entitled “Cl<strong>in</strong>ical trials <strong>in</strong> psychiatry: background and statistical perspective” (Statistical Methods <strong>in</strong><br />

Medical Research 1998:7:209‐234) <strong>in</strong> which he noted the existence of studies produced by psychiatrists that<br />

claim “<strong>in</strong>ord<strong>in</strong>ate enthusiasm” for certa<strong>in</strong> therapies.<br />

Dr Tony Johnson is the son‐<strong>in</strong>‐law of Dr Elizabeth Dowsett, who was formerly Medical Advisor to and<br />

President of the <strong>ME</strong> Association. Correspondence exists between an <strong>ME</strong>/CFS sufferer and Dr Johnson<br />

himself, but which also <strong>in</strong>volves Dr Anthony C Peatfield, Head of MRC Corporate Governance and Policy.<br />

The correspondence arose from Johnson’s Qu<strong>in</strong>quennial Report for the MRC’s Biostatistical Unit’s progress<br />

report for the years 2001 to 2006 that was placed on the website of the MRC Biostatistics Unit (BSU).<br />

Taken from the BSU’s Qu<strong>in</strong>quennial Review of 2006, one part of which states: “Our <strong>in</strong>fluence on policy‐<br />

makers has largely been <strong>in</strong>direct, through scientistsʹ work on advisory committees, <strong>in</strong> lead<strong>in</strong>g editorials, <strong>in</strong><br />

personal correspondence with M<strong>in</strong>isters, Chairs or Chief Executives (such as of Healthcare Commission or<br />

NICE), Chief Medical Officers and Chief Scientific Advisers, or through public dissem<strong>in</strong>ation when the<br />

media picks up on statistical or public health issues that our publications have highlighted.<br />

“The Unitʹs scientists must rema<strong>in</strong> wary of patient‐pressure groups. Tony Johnsonʹs work on chronic fatigue<br />

syndrome (CFS), a most controversial area of medical research, has had to counter vitriolic articles and<br />

websites ma<strong>in</strong>ta<strong>in</strong>ed by the more extreme charities and supported by some patient groups, journalists,<br />

Members of Parliament, and others, who have little time for research <strong>in</strong>vestigations”.<br />

This contention that “CFS” research is beset with vitriol and “extreme” charities was re‐iterated by Johnson<br />

himself <strong>in</strong> his own Report with<strong>in</strong> the Qu<strong>in</strong>quennial Review; under “Chronic Fatigue Syndrome (CFS), with<br />

P White, T Chalder (London), M Sharpe (Ed<strong>in</strong>burgh)”, Johnson’s Report stated:<br />

“CFS is currently the most controversial area of medical research and characterised by vitriolic articles and websites<br />

ma<strong>in</strong>ta<strong>in</strong>ed by the more extreme charities supported by some patient groups, journalists, Members of Parliament, and<br />

others, who have little time for research <strong>in</strong>vestigations. In response to a DH (Department of Health) Directive, MRC<br />

called for grant proposals for <strong>in</strong>vestigations <strong>in</strong>to CFS as a result of which two RCTs (PACE and FINE) were funded<br />

and have started despite active campaigns to halt them. I am part of the PACE study, a multi‐centre study compar<strong>in</strong>g<br />

cognitive behaviour therapy, graded exercise tra<strong>in</strong><strong>in</strong>g, and pac<strong>in</strong>g <strong>in</strong> addition to standardised specialist medical care<br />

(SSMC), with SSMC alone <strong>in</strong> 600 patients. I have been fully engaged <strong>in</strong> provid<strong>in</strong>g advice about design of PACE and I<br />

am a member of both Trial Management Group and Trial Steer<strong>in</strong>g Committee. I am not a PI (Pr<strong>in</strong>cipal <strong>Invest</strong>igator)<br />

because of familial <strong>in</strong>volvement with one of the charities, a perspective that has enabled me to play a vital role <strong>in</strong><br />

ensur<strong>in</strong>g that all <strong>in</strong>volved <strong>in</strong> the PACE trial ma<strong>in</strong>ta<strong>in</strong> absolute neutrality to all trial treatments <strong>in</strong> presentation,<br />

documentation and assessment”.<br />

Johnson’s Report on “CFS” research rang alarm bells with<strong>in</strong> the <strong>ME</strong>/CFS community, s<strong>in</strong>ce it openly stated<br />

that he, personally, had a “vital” role to play <strong>in</strong> ensur<strong>in</strong>g what ought to have been taken for granted <strong>in</strong> any<br />

MRC trial, namely the “absolute neutrality” of the PACE trial.<br />

Upon see<strong>in</strong>g this on the MRC Biostatistics Unit’s (BSU) website, an <strong>ME</strong>/CFS sufferer wrote first to the MRC<br />

Biostatistics Unit and then to Dr Johnson himself, request<strong>in</strong>g the names and details of all the charities,<br />

patient groups, journalists, Members of Parliament and “others” who have little time for research<br />

<strong>in</strong>vestigations, together with references for all the vitriolic articles and websites mentioned on the MRC BSU<br />

website.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!